ZETEZE ezetimibe/atorvastatin 10mg/20mg tablet blister pack

国家: 澳大利亚

语言: 英文

来源: Department of Health (Therapeutic Goods Administration)

有效成分:

atorvastatin calcium trihydrate, Quantity: 21.7 mg (Equivalent: atorvastatin, Qty 20 mg); ezetimibe, Quantity: 10 mg

可用日期:

ORGANON PHARMA PTY LTD

INN（国际名称）:

atorvastatin calcium trihydrate,Ezetimibe

药物剂型:

Tablet, multilayer

组成:

Excipient Ingredients: polysorbate 80; magnesium stearate; povidone; lactose monohydrate; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; calcium carbonate; hyprolose; silicon dioxide; titanium dioxide; macrogol 8000; hypromellose; purified talc

给药途径:

Oral

每包单位数:

10, 30

处方类型:

(S4) Prescription Only Medicine

疗效迹象:

Prevention of Cardiovascular Disease ZETEZE is indicated in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of LDL-C in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see Clinical Trials). Primary Hypercholesterolaemia ZETEZE is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: - not appropriately controlled with atorvastatin or ezetimibe alone; - or already treated with atorvastatin and ezetimibe Homozygous Familial Hypercholesterolaemia (HoFH) ZETEZE is indicated in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis).

產品總結:

Visual Identification: Capsule shaped, biconvex, white to off white tablets, with "333" debossed on one side of the tablet; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius

授权状态:

Licence status A

授权日期:

2015-02-04